Last reviewed · How we verify
Flubuperone (MELPERONE)
Flubuperone works by selectively blocking the D(3) dopamine receptor, which helps regulate mood and emotional responses.
Flubuperone, also known as Melperone, is a small molecule targeting the D(3) dopamine receptor. It belongs to the melperone drug class and is used to treat various psychiatric conditions. However, its commercial status and approved indications are unknown. The half-life of Flubuperone is approximately 3.9 hours, but its bioavailability and off-patent status are not available. As a result, its availability and usage are limited.
At a glance
| Generic name | MELPERONE |
|---|---|
| Drug class | melperone |
| Target | D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1D |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Imagine your brain has a system to control emotions and mood. Flubuperone helps by blocking a specific part of this system, called the D(3) dopamine receptor, which can become overactive in certain conditions. This helps to calm down excessive emotional responses and stabilize mood.
Approved indications
Common side effects
- General physical health deterioration
- Systemic infection
- Fall
- Pleurothotonus
- Drug interaction
- Epilepsy
- Haematemesis
- Sleep-related eating disorder
- Disorientation
- Medication error
- Peripheral circulatory failure
- Depressed level of consciousness
Key clinical trials
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)
- Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flubuperone CI brief — competitive landscape report
- Flubuperone updates RSS · CI watch RSS